GLP-1 Weight Loss Math 2026 — Mounjaro, Wegovy, Ozempic Projector

Tirzepatide weight loss 2026 (per SURMOUNT-1 NEJM 2022 + SURMOUNT-2 2024): MEAN 22.5% body weight loss at 72 weeks at maximum 15mg dose. EXAMPLES: 200 lb starting weight = ~45 lb loss = 155 lb final. 250 lb = ~56 lb loss = 194 lb. 300 lb = ~67 lb loss = 233 lb. RESPONDERS vs NON: 35% achieve >25% loss (super-responders). 30% achieve 15-25% loss. 25% achieve 5-15% loss. 10% achieve <5% loss (non-responders). DOSE-RESPONSE: 5mg dose ~14% loss. 10mg ~17%. 15mg ~22.5%. Higher dose = more loss but also more side effects. TIMELINE: Weeks 1-4 starter (2.5mg) — expect 1-3 lb loss + GI side effects. Weeks 5-12 titration up to 7.5mg — 8-12 lb cumulative. Weeks 13-24 — 15-20 lb cumulative. Weeks 25-52 — 25-35 lb cumulative. Weeks 53-72 — 30-50 lb cumulative depending on dose. PLATEAU EXPECTATION: weeks 12-20 first plateau common. Increase dose, increase activity, ensure protein adequacy. WHY DOES IT WORK: dual GLP-1 + GIP agonism reduces appetite (~20-30% calorie reduction) + slows gastric emptying + improves insulin sensitivity. Calorie deficit naturally occurs without effort. POST-DISCONTINUATION: 60-70% of weight regained within 1-2 years if no maintenance dose. Most patients need indefinite treatment.

GLP-1 drug efficacy ranking 2026 (mean weight loss at primary endpoint): 1. RETATRUTIDE (Lilly, Phase 3) — 24.2% at 48 weeks (Phase 2 data). FDA approval expected 2027. Triple GLP-1 + GIP + glucagon agonism — fastest weight loss. NOT YET AVAILABLE. 2. TIRZEPATIDE (Mounjaro/Zepbound) — 22.5% at 72 weeks. Available 2026. Dual GLP-1 + GIP. CURRENT CHAMPION. 3. CAGRISEMA (Novo, Phase 3) — 20.4% at 68 weeks. Combination GLP-1 + amylin. Phase 3 trials 2025-2026. Possible launch 2027. 4. SEMAGLUTIDE Wegovy — 14.9% at 68 weeks. Available 2026 (branded only post-2024 compound ban). 5. SEMAGLUTIDE Ozempic — 14.0% at 68 weeks. T2D-label, off-label for weight loss. 6. ORFORGLIPRON (Lilly oral) — 14.7% at 36 weeks. Oral pill, FDA submitted. 7. LIRAGLUTIDE (Saxenda) — 8.0%. Older drug, daily injection. PRACTICAL CHOICE 2026: Tirzepatide #1 IF available + insurance covers. Semaglutide if compounding still allowed in your state OR insurance only covers Wegovy. Avoid Saxenda — newer drugs better. ORAL OPTION: Orforglipron coming late 2026 — promises avoiding injections (huge for needle-phobic). RETATRUTIDE: wait if not weight-critical. Worth waiting for 24%+ loss + likely better tolerability profile.

GLP-1 insurance coverage 2026 — VARIES dramatically: COMMERCIAL EMPLOYER PLANS — coverage for Wegovy/Zepbound rising 2024-2026 (~50% of major employers cover). Required: prior auth + BMI ≥30 (or 27 with comorbidity) + obesity treatment plan. MEDICARE — 2024 reform allows obesity treatment coverage IF cardiovascular disease + obesity. Most Medicare patients still NOT covered for pure obesity. Type 2 diabetes Medicare patients DO get coverage. MEDICAID — varies by state. ~16 states cover. Most don't. CASH PRICE 2026: Mounjaro/Zepbound $1,100/mo. Wegovy $1,350/mo. Ozempic $1,000/mo. Saxenda $1,300/mo. ANNUAL out-of-pocket: $13,000-$16,000. DISCOUNT PROGRAMS: Lilly LillyDirect — discount via direct mail, ~$550/mo with valid prescription. Novo Nordisk Patient Savings — first-time users $25 first month, $499/mo ongoing IF commercial insurance + denial. NO INSURANCE OPTIONS: Lilly Insulin Affordability ($25/mo if income <400% poverty + uninsured). NEW DPC + telehealth services (Henry Meds, Sequence, Found Health) — $200-$400/mo for compounded semaglutide (legality varies post-2024 FDA crackdown). 2024 FDA RULING: shut down most compounded semaglutide (Novo trademark + supply restored). Compounded tirzepatide also under pressure. Telehealth options narrowing 2025-2026. STRATEGIC: pursue insurance approval first (BMI documentation + endocrinologist visit). Prior auth process ~2 weeks. WORTH IT for many — at 22% mean weight loss, lifetime healthcare savings often $50k+ vs not treating obesity.

Muscle preservation on GLP-1 2026 (per ISSN 2024 + endocrinologist consensus): RISK: 20-40% of weight loss on GLP-1 is LEAN MASS without intervention. Sarcopenia, weakness, slowed metabolism, rebound weight gain when stopping. PREVENTION strategies: (1) PROTEIN — increase to 1.2-1.6g per kg lean body weight (vs sedentary RDA 0.8g/kg). 200-lb person = 110-150g protein/day. SPLIT across 4-5 meals (24-30g each meal triggers muscle protein synthesis). (2) RESISTANCE TRAINING 3x/week minimum. Heavy compound lifts: squat, deadlift, press, pull. 8-15 reps × 3-4 sets. PROGRESSIVE OVERLOAD critical. (3) LEUCINE supplementation — 2-3g leucine per meal (or whey protein). Triggers MPS even with reduced calorie intake. (4) HYDRATION — GLP-1 drugs cause delayed gastric emptying + dehydration. 80-100 oz water daily. (5) MICRONUTRIENT density — focus on whole foods. GLP-1 reduces appetite ~30%; ensure remaining calories are nutrient-dense. (6) EAT EVEN WHEN NOT HUNGRY — common error: skipping meals due to lost appetite. Set timed meals + protein-first eating. (7) AVOID severe calorie deficit — let GLP-1 do work. Don't add additional restriction. Maintain 500-750 cal/day deficit max. (8) MONITOR — DEXA scan every 3 months tracks lean vs fat loss separately. WARNING SIGNS muscle loss: fatigue + weakness + slow strength gains in gym + frequent injury. STOP + reassess if 2+ symptoms. EXAMPLE PROTOCOL 200-lb person on tirzepatide: 130g protein/day (4 × 32g meals), 3x/week resistance training, 1g creatine/day, weekly weights + monthly DEXA. RESULT: 80%+ of weight loss as fat (vs 60% without intervention).

GLP-1 side effects 2026 — common + manageable but real: GASTROINTESTINAL (most common, 30-50% of users): NAUSEA — peaks weeks 2-4 of starter dose + after each titration. Most resolves within 4 weeks. Severity 1-3 of 10 typical. DIARRHEA — 15-20% experience. Lower-fat eating helps. CONSTIPATION — 10-15%. Fiber + magnesium. VOMITING — 5-10%, usually transient. ACID REFLUX — 10-15%. Avoid eating 2 hours before bed. SERIOUS but rare: PANCREATITIS — 0.1-0.3% incidence. Severe abdominal pain → ER. GALLSTONES — 1-2% (especially rapid weight loss). HYPOGLYCEMIA — rare unless diabetic on insulin. THYROID C-cell tumors — animal studies, rare in humans, MTC family history is contraindication. MUSCLE WASTING — addressed in protein/exercise. KIDNEY ISSUES — rare, monitor with annual labs. EMERGING 2024-2026 concerns: GASTROPARESIS (severe) — bowel motility issues persisting after discontinuation. 0.5-1% incidence. SUICIDAL IDEATION reports — investigated by FDA, no causal link confirmed yet. May be related to rapid weight loss + body image changes. EYE — diabetic retinopathy worsening in some T2D patients. NON-DIABETIC unaffected. MANAGEMENT TIPS: (1) Titrate UP slowly — don't rush dose increases. (2) Take with food. (3) Avoid high-fat meals (slowest digestion, highest nausea). (4) Sip water + small meals throughout day. (5) GINGER + crackers for nausea. (6) Ondansetron Rx for severe nausea. WHEN TO STOP: severe persistent vomiting, persistent abdominal pain, gallbladder symptoms, thyroid lump. Consult prescribing physician.

GLP-1 1-year weight projection 2026 (per published trial data): TIRZEPATIDE 15mg: 200 lb start → 172 lb at 52 wks (-14% mean). 250 lb → 215 lb. 300 lb → 258 lb. SEMAGLUTIDE 2.4mg: 200 → 184 lb (-8% mean at 52 wks before plateau). 250 → 230 lb. 300 → 276 lb. NOTE: peak loss takes 72 wks for tirzepatide, 68 wks for semaglutide. 1-year (52 wks) is approximately 2/3 of total expected loss. INDIVIDUAL VARIANCE: mean ±15% standard deviation. EXAMPLES of 200-lb individuals at 1 year on tirzepatide 15mg: 25th percentile: 162 lb (-19%). 50th percentile: 172 lb (-14%). 75th percentile: 184 lb (-8%). 90th percentile: 192 lb (-4% — non-responder). FACTORS for higher weight loss: female (slightly more), older (slightly more), higher starting BMI (more proportional), strict adherence to dose escalation, exercise + protein protocol, fewer side effects (continued dose increases). FACTORS for less loss: stopping due to side effects, irregular doses, low protein/exercise, continued high-calorie eating, starting at lower BMI (less to lose), genetic responsiveness. SCALE timing: most loss happens weeks 8-40. Plateau common weeks 41-52. Re-acceleration with dose increase. Maintenance phase begins post-72 weeks. GENERIC FORMULA for projection: starting_weight × (1 - 0.225) at 72 weeks for tirzepatide = realistic estimate. At 1 year: starting × (1 - 0.14). Adjust ±15% for personal variance. Compare to control diet (placebo arms): 2-4% loss at 72 weeks via diet/exercise alone in same trials. GLP-1 4-6x more effective.

GLP-1 long-term use 2026 reality: WEIGHT REGAIN AFTER STOPPING: 60-70% of lost weight typically regained within 1-2 years post-discontinuation. STEP-1 extension trial (semaglutide, 2 years post-stop): -5% net loss vs starting (started at -15%, regained 10%). Similar pattern tirzepatide. WHY: appetite returns to baseline. Insulin sensitivity reverts. Set point partly resets. CHOICES at end of treatment course: (1) STAY on indefinite low dose — research suggests maintenance dose 5-7.5mg tirzepatide preserves loss with fewer side effects. (2) WEAN to lower dose + maintain via behavior — small percentage successful. (3) STOP entirely — most regain. CURRENT MEDICAL CONSENSUS 2026: obesity is CHRONIC disease. GLP-1 is treatment, not cure. Comparable to insulin for diabetes — long-term use accepted. INSURANCE/COST FACTOR: $1,000-$1,400/month indefinitely = $12,000-$17,000/year ongoing. May not be sustainable for many. CARDIOVASCULAR BENEFIT: SELECT trial 2023 — semaglutide reduced major cardiovascular events 20% in obese non-diabetic patients. Long-term use may be CARDIOVASCULAR PRESCRIPTION even if weight stable. EMERGING: less-frequent dosing (once weekly is current; monthly versions in trials). LOWER-DOSE long-term may be standard 2027-2030. PERSONAL DECISION: (1) High risk of obesity complications (diabetes, hypertension) → continue indefinitely. (2) Aesthetic-only weight loss → may stop. (3) Insurance dependent — verify coverage long-term. (4) Lifestyle integration — those who restructure eating + exercise during treatment have best long-term outcomes after stopping. RECOMMENDATION: don't plan to stop. Plan for sustained treatment + lifestyle change. View GLP-1 as enabling tool for long-term obesity management rather than short-term diet.